Engineered bacteria for production and release of therapeutics
Some embodiments described herein relate to cells which have been genetically engineered to release a polypeptide when a population of the cells reaches a desired density. In some embodiments, the released polypeptide may be a therapeutic polypeptide. In some embodiments, the therapeutic polypeptide kills tumor cells or which inhibits the growth of tumor cells.
1. A method of treating a health condition in an individual, the method comprising administering one or more strains of cells to the individual,
wherein cells of the one or more strains of cells have been genetically engineered to release a polypeptide from the cells when a population of the cells reaches a desired density with a small number of such cells surviving and reseeding the population of cells,
wherein the reseeded population repeatedly regrows to the desired density leading to pulsatile lysis and release of the polypeptide,
wherein the cells comprise an engineered Synchronized Lysis Circuit (SLC), the SLC comprising a positive and a negative feedback loop,
wherein the positive feedback loop comprises: (i) a promoter operably linked to a positive feedback genetic element, and (ii) a degradation tagging sequence that encodes a degradation tag, and
wherein the positive feedback genetic element directly or indirectly activates the promoter, the degradation tag promotes the degradation of a protein encoded by the positive feedback genetic element, and the negative feedback loop promotes lysis of the cells.
2. The method of claim 1 , wherein the cells of the one or more strains of cells are bacterial cells.
3. The method of claim 2 , wherein the bacterial cells are anaerobic cells.
4. The method of claim 1 , wherein the polypeptide is a therapeutic polypeptide.
5. The method of claim 4 , wherein the therapeutic polypeptide is selected from the group consisting of:
(i) a polypeptide which kills tumor cells or which inhibits a growth of tumor cells,
(ii) a polypeptide which elicits immune responses against tumor cells,
(iii) a polypeptide which recruits T-cell or dendritic cells,
(iv) a polypeptide which causes or enhances apoptosis, and
(v) a polypeptide which enhances a release and/or efficacy of an anti-cancer drug.
6. The method of claim 5 , wherein the anti-cancer drug is a liposomal anti-cancer drug.
7. The method of claim 1 , wherein the cells of the one or more strains of cells are configured to proliferate within a tumor.
8. The method of claim 7 , wherein the cells are configured to proliferate in a necrotic region of a tumor.
9. The method of claim 1 , wherein a first strain of the one or more strains of cells is administered to the individual and allowed to proliferate for a desired period of time, and a second strain of the one or more strains of cells is subsequently administered to the individual and allowed to proliferate for a desired period of time, wherein proliferation of the first strain is prevented or inhibited as a result of the administration of the second strain.
10. The method of claim 9 , wherein the first strain is resistant to a first antibiotic and sensitive to a second antibiotic, and the second strain is resistant to the second antibiotic and sensitive to the first antibiotic, and wherein the first antibiotic is administered to the individual when proliferation of the first strain is desired, and the second antibiotic is administered to the individual when proliferation of the second strain is desired.
11. The method of claim 9 , wherein the first strain produces a first bacteriocin, configured to kill or inhibit a growth of a second strain, and the second strain produces a bacteriocin configured to kill or inhibit a growth of the first strain.
12. The method of claim 1 , wherein each of the strains of cells of the one or more strains of cells is administered to the individual in a cyclic manner.
13. The method of claim 1 , wherein a proliferation of only one of the one or more strains of cells in the individual is facilitated at a time while the proliferation of other strains of cells of the one or more strains of cells is prevented or inhibited.
14. The method of claim 1 , wherein a first strain of the one or more strains of cells is administered to the individual and allowed to proliferate for a desired period of time, a second strain of the one or more strains of cells is subsequently administered to the individual and allowed to proliferate for a desired period of time, and a third strain of the one or more strains of cells is subsequently administered to the individual and allowed to proliferate for a desired period of time, wherein the proliferation of the first strain is prevented or inhibited as a result of the administration of the second strain, and the proliferation of the second strain is prevented or inhibited as a result of the administration of the third strain.
15. The method of claim 14 , wherein the first strain produces a first bacteriocin configured to kill or inhibit a growth of a second strain, the second strain produces a bacteriocin configured to kill or inhibit a growth of the third strain, and the third strain produces a third bacteriocin configured to kill or inhibit a growth of the first strain.
16. The method of claim 1 , wherein the health condition is cancer.
17. A method of treating a health condition in an individual, the method comprising administering Flail one or more strains of cells to the individual,
wherein cells of the one or more strains of cells have been genetically engineered to release a polypeptide from the cells when a population of the cells reaches a desired density,
wherein the cells comprise an engineered Synchronized Lysis Circuit (SLC), the SLC comprising a positive and a negative feedback loop,
wherein the positive feedback loop comprises: (i) a promoter operably linked to a positive feedback genetic element, and (ii) a degradation tagging sequence that encodes a degradation tag, and
wherein the positive feedback genetic element directly or indirectly activates the promoter, the degradation tag promotes the degradation of a protein encoded by the positive feedback genetic element, and the negative feedback loop promotes lysis of the cells.
18. The method of claim 17 , wherein not all of the cells in the population are lysed when the population of the cells is at the desired density, thereby allowing regrowth of the cells after lysis and facilitating pulsatile release of the polypeptide.
19. The method of claim 17 , wherein a first strain of the one or more strains of cells is administered to the individual and allowed to proliferate for a desired period of time, and a second strain of the one or more strains of cells is subsequently administered to the individual and allowed to proliferate for a desired period of time, wherein the proliferation of the first strain is prevented or inhibited as a result of the administration of the second strain.
20. The method of claim 17 , wherein a first strain of the one or more strains of cells is administered to the individual and allowed to proliferate for a desired period of time, a second strain of the one or more strains of cells is subsequently administered to the individual and allowed to proliferate for a desired period of time, and a third strain of the one or more strains of cells is subsequently administered to the individual and allowed to proliferate for a desired period of time, wherein the proliferation of the first strain is prevented or inhibited as a result of the administration of the second strain, and the proliferation of the second strain is prevented or inhibited as a result of the administration of the third strain.